Retatrutide

Retatrutide is a triple hormone receptor agonist (GIP, GLP-1, glucagon) that people run primarily for weight loss and obesity management, with roughly 83% of 85 captured reports positive for weight loss and 84% of 44 reports positive for appetite control. Clinician references generally recommend starting at 1 mg weekly and titrating up to 12 mg weekly, subcutaneously, in cycles of roughly 1–4 weeks. The off-label evidence base is thinner than the discourse suggests, and most exploratory indications still lack posted results.

Retatrutide

Research Evidence

Evidence shape

Retatrutide holds moderate evidence: the strongest trials reach Phase 3, and the only blinded, posted results belong to obesity and type 2 diabetes. Thirty-three registered trials map twelve distinct indications, but only two have posted results; the rest are thin or exploratory, one remains animal-only, and six long-tail indications rest on a single trial. That concentration of data in obesity and diabetes, against sparse support everywhere else, is the signal.

Depthhow much
33 registered trials
18 completed · 2 with posted results · 15 recruiting / active · combined n=619
Breadthhow many areas
12 indications mapped
2 with results · 9 thin / exploratory · 1 animal-only · 6 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · AE rows aggregated from 2 trials · 9 linked publications on registered trials
Breadth and depth53 rows captured
Human
direct clinical signal
33
Animal
translational support
8
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
High Purity Peptides
HK
600 mg
$300.00
$0.5/mg
2
Trusted Peptide
unknown
10 mg
$8.00
$0.8/mg
3
Sentinel Valor
US
600 mg
$999.00
$1.67/mg
4
HCS Pharma (AU)
AU
15 mg
$26.95
$1.8/mg
5
Trustedpeps
US
30 mg
$54.95
$1.83/mg
6
Brit Peptides
UK
10 mg
$21.54
$2.16/mg

price offers can be sorted by column

1-6 of 103

Dosing & Protocol

How Retatrutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 18
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

18 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
1 mg1 mg – 12 mg
125 µg
500 µg
1 mg
3 mg
10 mg
Frequency
weekly
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 1 mg–12 mg weekly subQ (3 sources).

3 sources
Anecdotal
Community-reported real-world use · n = 102
Typical dose
1 mg125 µg – 12.5 mg
typical
125 µg
500 µg
1 mg
3 mg
10 mg
distribution of 64 reported doses · darker = more reports
By reported cadence
Daily1 mg (330 µg–1 mg) · n=2
Every other day1 mg · n=1
3×/week250 µg (125 µg–1.5 mg) · n=4
2×/week500 µg (500 µg–1.5 mg) · n=5
Every few days1 mg (200 µg–1 mg) · n=5
Weekly2 mg (250 µg–12 mg) · n=11
Schedule unstated2 mg (440 µg–12.5 mg) · n=26
Frequency
mixed
Timing
unspecified
Route
subQ
Cycle
unspecified

Reported doses span 125 µg–12.5 mg, most commonly 1 mg; schedules vary, most often weekly.

59 sources

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Retatrutide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.